[Digitalis therapy in practice: correlation between clinical evaluation and plasma digoxin concentration (author's...

Digitalis therapy has long been used to manage heart conditions, but the relationship between clinical symptoms and plasma drug levels remains unclear. Prior research has shown that digoxin affects cardiac function, but optimal dosing remains debated. Many studies focus on toxicity thresholds, but fewer examine how dosing correlates with symptom improvement. It was already known that renal function influences drug clearance, yet how this affects clinical outcomes is not fully understood. No prior work had resolved how maintenance dosages align with therapeutic ranges in real-world settings. This gap motivated a closer look at how clinical assessments compare to measured plasma concentrations. That uncertainty drove the need to evaluate whether current dosing guidelines are sufficient. This study aimed to clarify these clinical correlations.

The study aimed to assess how clinical evaluations align with plasma digoxin concentrations in patients on maintenance therapy. It sought to determine if current dosing practices are adequate for symptom improvement. The specific problem addressed was the lack of correlation between observed symptoms and measured drug levels. The motivation was to improve dosing accuracy and reduce under- or overdosing risks. The researchers wanted to evaluate if typical dosages provide therapeutic benefits or merely suboptimal levels. They also aimed to assess if renal function affects drug concentration ranges. This would help guide clinical decisions on dosage adjustments. The goal was to inform better therapeutic strategies based on measurable drug levels.

The study followed a prospective design involving 73 patients receiving maintenance digitalis therapy. Clinical evaluations were conducted to assess cardiac symptoms. Dosage adjustments were made based on observed symptoms. Plasma digoxin concentrations were measured on admission and on day 21 of treatment. The correlation between clinical findings and drug levels was analyzed. No specific statistical models were described in the abstract. The focus was on comparing observed symptoms with measured concentrations. The approach aimed to identify patterns in under- or overdosing trends.

Over half of the patients were found to be underdigitalized, suggesting insufficient dosing. Patients with low dosages and normal renal function often had no clinical indication for therapy. Usual maintenance dosages resulted in serum levels at the lower end of the therapeutic range. Patients with decompensation symptoms required higher dosages for improvement. Increasing dosages did not lead to toxicity in most cases. Patients with mild renal impairment had higher drug concentrations at standard dosages. These findings suggest a need for individualized dosing strategies. The results indicate that current guidelines may not always align with clinical needs.

The authors concluded that more than half of the patients were underdigitalized, indicating a need for dosage review. They proposed that low dosages in patients with normal renal function may be unnecessary. Standard dosages often result in suboptimal drug levels for symptom improvement. Patients with decompensation symptoms may benefit from increased dosages. The study suggests that higher dosages are generally safe in these cases. Mild renal impairment correlates with higher drug concentrations at usual dosages. These findings imply that clinical assessments should guide dosage adjustments. The authors propose that individualized dosing may improve therapeutic outcomes.